Stay updated on Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial
Sign up to get notified when there's something new on the Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial page.

Latest updates to the Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial page
- Check5 days agoChange DetectedRevision updated from v3.5.3 to v3.5.4, indicating a newer version of the site software used to render the ClinicalTrials.gov page. This maintenance update does not modify the study details, eligibility criteria, or results presented on the page.SummaryDifference0.0%

- Check12 days agoChange DetectedA new PubMed-listed publication citation has been added under Publications From PubMed, detailing a substudy related to the SENSCIS trial. This entry connects the trial to additional scholarly work and authors involved.SummaryDifference0.0%

- Check19 days agoNo Change Detected
- Check27 days agoChange DetectedThe only visible update is a change in the site’s displayed revision version at the bottom of the page from **v3.5.2** to **v3.5.3**.SummaryDifference0.0%

- Check34 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check41 days agoChange DetectedReplaced Padua, Italy, 35128 with Padova, Italy, 35128 to reflect the local official name.SummaryDifference0.0%

- Check48 days agoChange DetectedSystemic sclerosis was added as the disease term and Scleroderma removed where it referred to the same condition.SummaryDifference0.0%

Stay in the know with updates to Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial page.